ArticleCurrent infectious disease reports2010
Early antimicrobial therapy in severe sepsis and septic shock.
Article in Current infectious disease reports, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05511129 (Tolerance and Efficacy of Amiklin Administration During Nosocomial Infections Complicating COVID-19 in the ICU), which is not on this map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Tolerance and Efficacy of Amiklin Administration During Nosocomial Infections Complicating COVID-19 in the ICU
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Effectiveness and safety of procalcitonin evaluation for reducing mortality in adults with sepsis, severe sepsis or septic shock.The Cochrane database of systematic reviews · 2017Pooled it
- Early Versus Late Antipseudomonal β-Lactam Antibiotic Dose Adjustment in Critically Ill Sepsis Patients With Acute Kidney Injury: A Prospective Observational Cohort Study.Open forum infectious diseases · 2024Trial
- Vasopressin compared with norepinephrine augments the decline of plasma cytokine levels in septic shock.American journal of respiratory and critical care medicine · 2013Trial
- PScientific reports · 2026Observational
- Phage cocktail amikacin combination as a potential therapy for bacteremia associated with carbapenemase producing colistin resistant Klebsiella pneumoniae.Scientific reports · 2024Article
- Optimization of Empirical Antimicrobial Therapy inAntibiotics (Basel, Switzerland) · 2023Article
- Is procalcitonin a reliable indicator of sepsis in spinal cord injury patients: an observational cohort study.European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society · 2023Observational
- Shortening identification times: comparative observational study of three early blood culture testing protocols.Frontiers in cellular and infection microbiology · 2023Observational
- Duplex dPCR System for Rapid Identification of Gram-Negative Pathogens in the Blood of Patients with Bloodstream Infection: A Culture-Independent Approach.Journal of microbiology and biotechnology · 2021Article
- Can the cytokine adsorber CytoSorbAnnals of intensive care · 2021Article
- Pharmacokinetics of meropenem in children with sepsis undergoing extracorporeal life support: A prospective observational study.Journal of clinical pharmacy and therapeutics · 2021Observational
- [Reducing mortality in adults with sepsis, severe sepsis, or septic shock: effectiveness and safety of procalcitonin].Der Urologe. Ausg. A · 2021Review
- Physiologically Based Population Pharmacokinetic Modeling Approach for Ciprofloxacin in Bone of Patients Undergoing Orthopedic Surgery.ACS pharmacology & translational science · 2020Article
- Therapeutic Drug Monitoring of Meropenem and Piperacillin in Critical Illness-Experience and Recommendations from One Year in Routine Clinical Practice.Antibiotics (Basel, Switzerland) · 2020Article
- Direct-from-blood RNA sequencing identifies the cause of post-bronchoscopy fever.BMC infectious diseases · 2019Article
- Using multiple 'omics strategies for novel therapies in sepsis.Intensive care medicine · 2018Article
- Role of renal function in risk assessment of target non-attainment after standard dosing of meropenem in critically ill patients: a prospective observational study.Critical care (London, England) · 2017Observational
- Decreased serum concentrations of sphingosine-1-phosphate in sepsis.Critical care (London, England) · 2015Article
- Antibiotic stewardship in the intensive care unit.Critical care (London, England) · 2014Review
- The meta-genome of sepsis: host genetics, pathogens and the acute immune response.Journal of innate immunity · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The advent of modern antimicrobial therapy following the discovery of penicillin during the 1940s yielded remarkable improvements in the case fatality rates of serious infections, including septic shock. Since then, pathogens have continuously evolved under selective antimicrobial pressure, resulting in a lack of additional significant improvement in clinical effectiveness of antimicrobial therapy of septic shock despite ever more broad-spectrum and potent drugs. In addition, although substantial effort and money were expended on the development of novel nonantimicrobial therapies of sepsis in the past 30 years, clinical progress in this regard has been limited. This article explores the possibility that the key to significant improvement in the outcome of septic shock may lie, in great part, with improvements in delivery of existing antimicrobials. Recognizing the role of delays in administration of antimicrobial therapy in the poor outcomes of septic shock is central to this effort.
Identifiers
21308515What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.